Nie Haichen, Su Yongchao, Zhang Mingtao, Song Yang, Leone Anthony, Taylor Lynne S, Marsac Patrick J, Li Tonglei, Byrn Stephen R
Department of Industrial and Physical Pharmacy, Purdue University , 575 Stadium Mall Drive, West Lafayette, Indiana 47907, United States.
Formulation Sciences, Teva Pharmaceuticals , 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States.
Mol Pharm. 2016 Nov 7;13(11):3964-3975. doi: 10.1021/acs.molpharmaceut.6b00740. Epub 2016 Oct 4.
It has been technically challenging to specify the detailed molecular interactions and binding motif between drugs and polymeric inhibitors in the solid state. To further investigate drug-polymer interactions from a molecular perspective, a solid dispersion of clofazimine (CLF) and hypromellose phthalate (HPMCP), with reported superior amorphous drug loading capacity and physical stability, was selected as a model system. The CLF-HPMCP interactions in solid dispersions were investigated by various solid state spectroscopic methods including ultraviolet-visible (UV-vis), infrared (IR), and solid-state NMR (ssNMR) spectroscopy. Significant spectral changes suggest that protonated CLF is ionically bonded to the carboxylate from the phthalyl substituents of HPMCP. In addition, multivariate analysis of spectra was applied to optimize the concentration of polymeric inhibitor used to formulate the amorphous solid dispersions. Most interestingly, proton transfer between CLF and carboxylic acid was experimentally investigated from 2D H-H homonuclear double quantum NMR spectra by utilizing the ultrafast magic-angle spinning (MAS) technique. The molecular interaction pattern and the critical bonding structure in CLF-HPMCP dispersions were further delineated by successfully correlating ssNMR findings with quantum chemistry calculations. These high-resolution investigations provide critical structural information on active pharmaceutical ingredient-polymer interaction, which can be useful for rational selection of appropriate polymeric carriers, which are effective crystallization inhibitors for amorphous drugs.
在固态下明确药物与聚合物抑制剂之间详细的分子相互作用和结合基序在技术上具有挑战性。为了从分子角度进一步研究药物 - 聚合物相互作用,选择了氯法齐明(CLF)与邻苯二甲酸羟丙甲纤维素(HPMCP)的固体分散体作为模型系统,该固体分散体具有报道的优异无定形药物负载能力和物理稳定性。通过各种固态光谱方法,包括紫外可见(UV-vis)、红外(IR)和固态核磁共振(ssNMR)光谱,研究了固体分散体中CLF - HPMCP的相互作用。显著的光谱变化表明质子化的CLF与HPMCP邻苯二甲酰取代基的羧酸盐形成离子键。此外,应用光谱的多变量分析来优化用于制备无定形固体分散体的聚合物抑制剂的浓度。最有趣的是,利用超快魔角旋转(MAS)技术从二维H - H同核双量子NMR光谱实验研究了CLF与羧酸之间的质子转移。通过成功地将ssNMR结果与量子化学计算相关联,进一步描绘了CLF - HPMCP分散体中的分子相互作用模式和关键键合结构。这些高分辨率研究提供了关于活性药物成分 - 聚合物相互作用的关键结构信息,这对于合理选择合适的聚合物载体可能是有用的,这些聚合物载体是无定形药物的有效结晶抑制剂。